Advertisement

Urolithiasis pp 215-215 | Cite as

Modulation of Calcium-Oxalate-Monohydrate Crystallization Kinetics in Vitro

  • D. J. Kok
  • S. E. Papapoulos
  • I. Que
  • O. L. M. Bijvoet

Abstract

Urinary and model compounds were tested in a seeded-crystal growth system in which the effects of additives on the solubility, the growth, and the agglomeration of calcium-oxalate-monohydrate (COM) crystals are measured separately (1). Heparin (0.05–10 μM), chondroitin sulfate (0.1–10 μM), pentosanpolysulfate (1–100 μM),, pyrophosphate (1–100 μM),, citrate (0.05–2.5 mM), magnesium (0.5–10 mM), and phosphate (0.3–30 mM) were tested. The solubility of COM crystals was increased strongly by citrate and magnesium. The crystal growth was inhibited by all compounds tested. However, the high-molecular-weight compounds were the strongest inhibitors at low concentrations already. In contrast, inhibition of crystal agglomeration was achieved only by the low-molecular-weight compounds, and citrate was the most potent inhibitor at concentrations likely to be found in normal urine. The high-molecular-weight substances, despite their strong effect on growth, had no effect on agglomeration. When heparin and citrate were tested together, crystal-growth inhibition was exerted mainly by heparin, while agglomeration was inhibited exclusively by citrate. A combination of citrate with various concentrations of magnesium or various calcium/oxalate ratios, showed that the inhibitory effect of citrate on agglomeration can be modulated by the concentrations of magnesium and calcium present, the active form of citrate probably being its complex with magnesium or calcium.

Keywords

Public Health Crystal Growth Active Form Potent Inhibitor Model Compound 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    OLM Bijvoet, LJML Blomen, EJ Will, and H Linden, J. Crystal Growth 64: 297 (1983).CrossRefGoogle Scholar
  2. 2.
    DJ Kok, SE Papapoulos, and OLM Bijvoet, Lancet i: 1056 (1986).CrossRefGoogle Scholar
  3. 3.
    DJ Kok, SE Papapoulos, I Que, and OLM Bijvoet, in: this volume, p. 105.Google Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • D. J. Kok
    • 1
  • S. E. Papapoulos
    • 1
  • I. Que
    • 1
  • O. L. M. Bijvoet
    • 1
  1. 1.Department of EndocrinologyUniversity HospitalLeidenThe Netherlands

Personalised recommendations